These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36275723)

  • 1. On the role of allergen-specific IgG subclasses for blocking human basophil activation.
    Zinkhan S; Thoms F; Augusto G; Vogel M; Bachmann MF
    Front Immunol; 2022; 13():892631. PubMed ID: 36275723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of IgG
    Strobl MR; Demir H; Sánchez Acosta G; Drescher A; Kitzmüller C; Möbs C; Pfützner W; Bohle B
    J Allergy Clin Immunol; 2023 May; 151(5):1371-1378.e5. PubMed ID: 36657603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy.
    Kanagaratham C; El Ansari YS; Lewis OL; Oettgen HC
    Front Immunol; 2020; 11():603050. PubMed ID: 33362785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
    Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro basophil histamine-releasing activity of circulating IgG1 and IgG4 autoanti-IgE antibodies from asthma patients and the demonstration that anti-IgE modulates allergen-induced basophil activation.
    Shakib F; Smith SJ
    Clin Exp Allergy; 1994 Mar; 24(3):270-5. PubMed ID: 7516815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.
    Cady CT; Powell MS; Harbeck RJ; Giclas PC; Murphy JR; Katial RK; Weber RW; Hogarth PM; Johnson S; Bonvini E; Koenig S; Cambier JC
    Immunol Lett; 2010 May; 130(1-2):57-65. PubMed ID: 20004689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen-specific IgG show distinct patterns in persistent and transient food allergy.
    McKendry RT; Kwok M; Hemmings O; James LK; Santos AF
    Pediatr Allergy Immunol; 2021 Oct; 32(7):1508-1518. PubMed ID: 34057765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in allergen-specific basophil activation and T cell proliferation in atopic dermatitis patients with comorbid allergic rhinoconjunctivitis treated with a monoclonal anti-IL-4Rα antibody or allergen-specific immunotherapy.
    Layritz AS; Galicia-Carreón J; Benfadal S; Novak N
    Immun Inflamm Dis; 2023 Apr; 11(4):e808. PubMed ID: 37102639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb.
    Wigginton SJ; Furtado PB; Armour KL; Clark MR; Robins A; Emara M; Ghaemmaghami AM; Sewell HF; Shakib F
    Clin Exp Allergy; 2008 Feb; 38(2):313-9. PubMed ID: 18070161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of human IgG4 subclass with allergen-specific blocking activity.
    Lambin P; Bouzoumou A; Murrieta M; Debbia M; Rouger P; Leynadier F; Levy DA
    J Immunol Methods; 1993 Sep; 165(1):99-111. PubMed ID: 8409473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.
    Burton OT; Logsdon SL; Zhou JS; Medina-Tamayo J; Abdel-Gadir A; Noval Rivas M; Koleoglou KJ; Chatila TA; Schneider LC; Rachid R; Umetsu DT; Oettgen HC
    J Allergy Clin Immunol; 2014 Dec; 134(6):1310-1317.e6. PubMed ID: 25042981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions.
    James LK; Till SJ
    Curr Allergy Asthma Rep; 2016 Mar; 16(3):23. PubMed ID: 26892721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.
    Shamji MH; Kappen JH; Akdis M; Jensen-Jarolim E; Knol EF; Kleine-Tebbe J; Bohle B; Chaker AM; Till SJ; Valenta R; Poulsen LK; Calderon MA; Demoly P; Pfaar O; Jacobsen L; Durham SR; Schmidt-Weber CB
    Allergy; 2017 Aug; 72(8):1156-1173. PubMed ID: 28152201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy.
    Rodríguez-Domínguez A; Berings M; Rohrbach A; Huang HJ; Curin M; Gevaert P; Matricardi PM; Valenta R; Vrtala S
    J Allergy Clin Immunol; 2020 Nov; 146(5):1097-1108. PubMed ID: 32298697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses.
    Ejrnaes AM; Bodtger U; Larsen JN; Svenson M
    Mol Immunol; 2004 Jul; 41(5):471-8. PubMed ID: 15183926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal allergen-neutralizing IgG
    Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
    J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy.
    Djurup R
    Allergy; 1985 Oct; 40(7):469-86. PubMed ID: 3907393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy.
    Möbs C; Müller J; Rudzio A; Pickert J; Blank S; Jakob T; Spillner E; Pfützner W
    Allergy; 2015 Jun; 70(6):715-9. PubMed ID: 25753563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.